Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
This study is currently recruiting participants.
Verified March 2013 by Astellas Pharma Inc
Study NCT01390337   Information provided by Astellas Pharma Inc

First Received on July 7, 2011.   Last Updated on March 25, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia, Myeloid, Acute
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
AC220
daunorubicin
cytarabine
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Astellas Pharma Inc
Ambit Biosciences Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services